Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2505 - A Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)


10 Sep 2017


Poster display session


David McDermott


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


D.F. McDermott1, R.W. Joseph2, T. Ho3, U. Vaishampayan4, S. Ali5, M. Matrana6, R. Alter7, J. Edenfield8, S. Blanchette9, L. Gan9, M.B. Atkins10

Author affiliations

  • 1 Hematology/oncology, Beth Israel Deaconess Medical Center, 02215 - Boston/US
  • 2 Department Of Hematology/oncology, Mayo Clinic, 32224 - Jacksonville/US
  • 3 Oncology, Mayo Clinic, Phoenix/US
  • 4 Solid Tumor Oncology, Wayne State University, Karmanos Cancer Center, Detroit/US
  • 5 Oncology And Hematology, Franciscan Health, Indianapolis/US
  • 6 Hematology Oncology, Ochsner Health, New Orleans/US
  • 7 Head And Neck & Urologic Oncology, Hackensack University Medical Center, Hackensack/US
  • 8 Institute For Translational Oncology Research, Greensville Health System, Greensville/US
  • 9 Clinical Research, X4 Pharmaceuticals, Cambridge/US
  • 10 Oncology, Lombardi Cancer Center Georgetown University, 20007 - Washington DC/US


Abstract 2505


X4P-001 is an oral, selective, allosteric inhibitor of the chemokine receptor CXCR4, and has been shown to down-regulate hypoxia inducible factor-2α (HIF-2α) and myeloid-derived suppressor cell (MDSC) trafficking in the tumor microenvironment. In multiple RCC xenograft models, the addition of X4P-001 to tyrosine kinase inhibitors (TKIs), including axitinib, increases the efficacy and delays the onset of TKI resistance.


This is an ongoing phase 1/2 open-label study of X4P-001 in combination with axitinib in patients (pts) with histologically confirmed clear cell RCC who have received ³1 prior systemic therapy. The Ph1 portion of the study evaluates safety, tolerability, PK, PD and anti-tumor activity of the combination using a 3 + 3 dose escalation schema (escalating doses of X4P-001+ axitinib at 5 mg BID).


As of 27 April, 2017, sixteen (16) pts were enrolled in the Ph1 portion of the study. The median age was 64 years (range 50-76) and pts had received a median of 2 prior lines of therapy (range 1-5). The doses tested were 200 mg BID, 400 and 600 mg QD of X4P-001 + axitinib. Two doses limiting toxicities (DLTs) were observed at the X4P-001 600 mg QD dose level: one pt had multiple grade (G) 2 adverse events (AEs), including anorexia, cognitive disturbance, fatigue, nausea, vomiting, and somnolence; another pt had G3 dyspnea and fatigue. The MTD/RP2D was determined to be 400 mg QD of X4P-001 + axitinib. Treatment-related AEs (≥ 10%) of any grade were fatigue, diarrhea, hypertension, nausea, headache, anorexia, vomiting, dysphonia, proteinuria, dry eye, dry mouth, arthralgia, chest pain, cognitive disorder, dysgeusia, stomatitis, weight loss, and elevated creatinine. Treatment-related G3/4 AEs (≥ 10%) were fatigue and hypertension. In addition, one pt had SAE due to G2 diarrhea and G2 creatinine elevation. Of the 9 clinically evaluable pts, 3 had confirmed partial response, 5 had stable disease, and 1 had progressive disease. Median duration on treatment was 6.0 months (range 4.6-12.1).


The combination treatment of X4P-001 and axitinib is well tolerated with preliminary evidence of clinical activity. The Ph2 portion of the study is ongoing.

Clinical trial identification

NCT02667886 First received: January 20, 2016

Legal entity responsible for the study

X4 Pharmaceuticals


X4 Pharmaceuticals


D.F. McDermott: Paid consultant to Bristol-Myers Squib, Pfizer, Merck, Novartis, Eisai, Exelixis, Array BioPharm, Genentech BioOncology and receives research support from Prometheus S. Blanchette, L. Gan: Employee of X4 Pharmaceuticals. M.B. Atkins: Compensated consultant for Bristol-Myers Squibb, Merck, Roche, Pfizer, Novartis, Peleton, AstraZeneca, Nektar, Acceleron, Eisai and Exelixis and serve on Advisory Boards for X4 Pharma, Merck, Novartis, Roche, Pfizer, Galactone, Agenus and AVEO. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.